TABLE 3.
Baseline characteristics of the study population and prevalence of the metabolic syndrome and of its components in case-control studies
| Total population | VTE patients | Controls | P | |
|---|---|---|---|---|
| Number | 2702 | 908 | 1794 | - |
| Males, n (%) | 1162 (43.0) | 475 (52.3) | 687 (38.3) | <0.001 |
| Mean age, y (SD) | 51.4 (14.3) | 52.7 (15.3) | 50.7 (13.7) | 0.001 |
| Obesity*, n (%) | 686 (25.4) | 313 (34.5) | 373 (20.8) | <0.001 |
| Cholesterol >200 mg/dL°, n (%) | 1253 (46.4) | 475 (52.3) | 778 (43.4) | <0.001 |
| LDL cholesterol >160 mg/dL°, n (%) | 548 (20.3) | 257 (28.3) | 291 (16.2) | <0.001 |
| Metabolic syndrome, n (%) | 703 (26.0) | 341 (37.6) | 362 (20.2) | <0.001 |
| Abdominal obesity†, n (%) | 1066 (39.5) | 466 (51.3) | 600 (33.4) | <0.001 |
| Fasting glucose ≥100 mg/dL°, n (%) | 720 (26.6) | 314 (34.6) | 406 (22.6) | <0.001 |
| Blood pressure ≥130/85 mmHg°, n (%) | 1052 (38.9) | 440 (48.5) | 612 (34.1) | <0.001 |
| HDL cholesterol <40/50 mg/dL°, n (%) | 773 (28.6) | 365 (40.2) | 504 (28.1) | <0.001 |
| Triglycerides≥150 mg/dL°, n (%) | 641 (23.7) | 283 (31.2) | 358 (20.0) | <0.001 |
VTE: venous thromboembolism, SD: standard deviation
*
Caucasian patients: BMI > 30 Kg/m2 Asian patients: BMI > 25 Kg/m2
†
Caucasian patients: waist circumference > 102 cm for men and > 88 cm for women; Asian patients: waist circumference > 90 cm for men and > 80 cm for women
°
Patients currently receiving drug therapy for hypertension, diabetes, or dyslipidemia (only statins) were defined as having those disorders.